Anthropic appointed Vas Narasimhan, Novartis CEO, to its board of directors, as reported by WSJ on April 14, 2026.
This follows February addition of former Microsoft and GM executive Chris Liddell, marking the second board addition in recent months.
Anthropic is strengthening its board while considering an IPO as early as 2026 and expanding its enterprise push into healthcare.
The firm partnered with Eli Lilly, Novo Nordisk and Genmab to shorten drug development, and Daniela Amodei noted Narasimhan oversaw 35+ novel medicines.